Retardation of brain aging by chronic treatment with melatonin.
Slowing the functional decline in the aging brain is not only relevant to nonpathological senescence but also to a broad range of neurodegenerative diseases. Although disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are not found in the young adult, they gradually manifest with increasing age. AD, in particular, is an increasing major public health concern as the population ages; therapies that delay disease onset will markedly reduce overall disease prevalence. Aging of the brain has been repeatedly associated with cumulative oxidative damage to macromolecules and to abnormal levels of inflammatory activity. Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence. Recent research has focused on supplementation with dietary melatonin designed to elucidate the specific key intracellular targets of age-related inflammatory events, and the optimal means of affording protection of these targets. This report summarizes the progress made in this area.
Bondy
S C
SC
Department of Community and Environmental Medicine, University of California, Irvine, 92697-1825, USA. scbondy@uci.edu
Lahiri
D K
DK
Perreau
V M
VM
Sharman
K Z
KZ
Campbell
A
A
Zhou
J
J
Sharman
E H
EH
D000375:Aging / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D016207:Cytokines / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology; D008550:Melatonin / Q000008:administration & dosage*; D019636:Neurodegenerative Diseases / Q000150:complications / Q000188:drug therapy*; D018384:Oxidative Stress / Q000187:drug effects
D016207:Cytokines; D008550:Melatonin